MINERVA ENDOMETRIAL ABLATION SYSTEM
Axora Medical, Inc. · Decision date Jul 27, 2015
What did the FDA approve?
FDA PMA P140013 is an approval for the MINERVA ENDOMETRIAL ABLATION SYSTEM. The database entry states the device category as a thermal ablation endometrial device and the specialty as Obstetrics/Gynecology, but it does not add any technical details beyond the named system and its field label.
The stated scope is ablation of the endometrial lining of the uterus in pre-menopausal women with menorrhagia due to benign causes, for whom childbearing is complete. This is the approval statement for the PMA record itself; the supplied data do not describe a supplement, a later change, or any separate manufacturing notice.
FDA approval order statement
APPROVAL FOR THE MINERVA ENDOMETRIAL ABLATION SYSTEM. THIS DEVICE IS INDICATED FOR ABLATION OF THE ENDOMETRIAL LINING OF THE UTERUS IN PRE-MENOPAUSAL WOMEN WITH MENORRHAGIA (EXCESSIVE BLEEDING) DUE TO BENIGN CAUSES FOR WHOM CHILDBEARING IS COMPLETE.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Jul 27, 2015
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140013
- Regulatory pathway
- Premarket approval application
- Applicant
- Axora Medical, Inc.
- Product code
- MNB
- Decision code
- APPR
- Decision date
- Jul 27, 2015
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, thermal ablation, endometrial.
- Applicant
- Axora Medical, Inc.
- Product code
- MNB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P140013 received
Application receipt date recorded by FDA.
P140013 · FDA decision
APPR
P140013/S019 · Related supplement
MINERVA ENDOMETRIAL ABLATION SYSTEM
Timeline entries are records held by MedtechLedger for P140013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MINERVA ENDOMETRIAL ABLATION SYSTEMP140013/S019 | Axora Medical, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Explore the linked device profile
Other records with product code MNB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Channel Medsystems, Inc. | PMA supplement | Nov 3, 2026 | FDA | |
Cerene Cryotherapy DeviceP180032/S024 | Channel Medsystems, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Cerene Cryotherapy DeviceP180032 | Channel Medsystems, Inc. | PMA approval | Mar 28, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Axora Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1 Independent Dr. Suite 2300, Jacksonville, FL, 32202
Sources and methodology
- Original FDA record: P140013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


